Breast B1-Rads3

Breast BI-RADS 3 usually indicates that the breast lesion may be benign, but close follow-up is needed. BIRADS classification is an evaluation system for breast imaging results. BIRADS 3 indicates that the breast lesion has a low likelihood of malignancy, generally less than 2%. This conclusion is based on a combination of imaging features, such as shape, borders, and internal echoes of the mass. Although the likelihood of malignancy is low, it does not mean that malignancy can be ruled out completely. Therefore, close follow-up observation is important. It is usually recommended to reexamine in a short period of time, such as about 6 months, to monitor for changes in the lesion. If the lesion remains stable or becomes smaller, regular follow-up is sufficient; however, if abnormalities such as enlargement and morphological changes occur, further evaluation may be required, such as biopsy. For patients assessed as BIRADS 3, the doctor will inform them in detail, including malignant risk and follow-up recommendations. Patients need to fully understand and actively cooperate with follow-up, while maintaining attention to their own breast health, such as self-examination. If any new symptoms occur during follow-up, such as increased breast pain, sudden swelling, nipple discharge, etc., they should seek medical attention promptly. In addition, other factors may affect the diagnosis and management of BIRADS 3 lesions. For example, the patient's age, family history, past medical history, etc. If the patient has a family history of breast cancer or other risk factors, more caution may be needed, and closer follow-up or other further measures may be considered. Breast BI-RADS 3 indicates a high likelihood of benign disease, but attention and close follow-up are still needed to detect possible changes in time and take appropriate measures. Patients should communicate fully with their doctors to develop appropriate follow-up and management protocols.